david miklos, md, phd, describes the optimal way to use ibrutinib in the treatment of gvhd
Published 6 years ago • 54 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:51
david miklos, md, phd, explains how ibrutinib is being studied for the treatment of gvhd
-
3:27
david miklos, md, discusses the outcomes in the phase 2 ibrutinib study for chronic gvhd
-
4:33
integrate: 2-year follow-up of ibrutinib plus corticosteroids for cgvhd
-
4:41
despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
-
21:21
clinical impact of h-y alloimmunization by david miklos, md, phd
-
1:49
david miklos, md, on the impact stem cell and bone marrow transplant have on patients
-
23:32
hypocellular mds vs. aplastic anemia - diagnosis and therapy
-
1:02:28
treatment update: myelodysplastic syndromes (mds)
-
18:48
mycophenolate mofetil - role in interstitial lung diseases
-
3:15
updates on the use of btkis in the treatment of mcl
-
1:26
adverse events associated with btkis in the treatment of waldenström’s macroglobulinemia
-
1:03
the importance of the mdt in managing transplant survivors
-
1:29
dr. miklos on development process for kte-x19 in mcl
-
5:11
recently approved avp-825 provides meaningful pain relief for patients with migraine
-
9:41
the i4mds consortium and immune monitoring in mds
-
2:23
dcr bioreg recipient: dr. miklos molnar
-
1:46
dr. hyman on a phase i study of the angiopoietin-2 inhibitor medi3617
-
2:46
why is it important for cardiologists and hematologists to work closely together?
-
54:00
2022 spf conference - hiroshi mitsumoto, md, dsc
-
2:23
john durkin, md: benefits of confocal microscopy versus biopsy
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
13:12
immunologic treatment advancements in lymphoma